Drug Discovery@nature.com 22 July 2011

Advertisement Need to safety assess a human Cytochrome P450 metabolite? Learn more from Taconic. TABLE OF CONTENTS 22 July 2011 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Chemical Biology Symposium 2011: Cancer Chemical Biology October 20-22, 2011 • Cambridge, MA, USA The 2011 symposium will explore the chemical biology of cancer in terms of therapeutic opportunities and a comprehensive view of cancer biology. For more information and to register, visit: www.nature.com/natureconferences/nchembio2011   News Top Psoriasis: from bed to bench and back doi:10.1038/nbt.1906 Advances in immunology, a focus on human tissue and a dash of luck have given dermatologists several highly effective psoriasis therapies, of which Stelara is the latest. Full Text Biologic Indian detour adds value doi:10.1038/nbt0711-561c In a neat example of the globalization of drug discovery, an Indian company sells profitably to a Western pharma a drug originally developed in the West. Full Text A shortage link? doi:10.1038/nm0711-761b Not everyone agrees about who is to blame for "an unprecedented surge in drug shortages in the United States". Full Text Straight talk with...Valery Danilenko doi:10.1038/nm0711-764 Valery Danilenko, who leads the biotechnology division at the Vavilov Institute of General Genetics in Moscow, talks to Nature Medicine about the US-Russian Scientific Forum. Full Text Analysis Top Gladstone's AD venture doi:10.1038/scibx.2011.754 UCSF's Gladstone Institute of Neurological Disease is launching a philanthropically funded translational research center to organize the preclinical development of its Alzheimer's disease candidates and ready them for commercialization through startups or licensing deals. Full Text Timing of patent filing and market exclusivity doi:10.1038/nrd3494 This analysis article looks at the relationship between patent filing date, market authorization date and expected duration of market exclusivity over the period 2000 to 2010. Full Text Fresh from the pipeline: Pirfenidone doi:10.1038/nrd3495 Pirfenidone (Esbriet; Intermune) has been granted marketing authorization in Europe for the treatment of idiopathic pulmonary fibrosis. In October 2008 it was approved for the same indication in Japan, where it is marketed as Pirespa. Full Text Research Highlights Top Metabolic disease: New role for HDACs in glucose homeostasis doi:10.1038/nrd3483 Two papers have found a novel mechanism involved in the regulation of glucose production by the liver, implicating class IIa histone deacetylases (HDACs) as promising therapeutic targets. Full Text Inflammatory disorders: Steroids modulate microglia-mediated inflammation doi:10.1038/nrd3485 Researchers have identified a gene-repression pathway that regulates microglia-induced inflammation. This pathway could be targeted using certain ERβ ligands as a new approach to treat neurodegenerative diseases. Full Text Cancer: Autophagy presents Achilles heel in melanoma doi:10.1038/nrd3482 Melanoma cells with an activated RAS–MEK–signalling pathway fail to induce autophagy upon leucine withdrawal. The combination of an autophagy inhibitor and a leucine-free diet can synergistically inhibit tumour growth. Full Text Research & Reviews Top How were new medicines discovered? doi:10.1038/nrd3480 Analysis suggests a target-centric approach for first-in-class drugs, without consideration of an optimal molecular mechanism of action, may contribute to the current high attrition rates and low productivity in pharmaceutical research. Full Text Novel therapeutic targets for the treatment of heart failure doi:10.1038/nrd3431 This review of new therapeutic targets and future perspectives of new drugs looks also at the possible explanations for the discrepancy between data from Phase II and Phase III trials. Full Text Structure of the human histamine H1 receptor complex with doxepin doi:10.1038/nature10236 The crystal structure of the H1R complex with doxepin, a first-generation H1R antagonist, sheds light on the molecular basis of H1R antagonist specificity against H1R. Full Text Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition doi:10.1038/nm.2377 Inhibition of Cdk1 represents a plausible strategy for expanding the utility of PARP inhibitors to BRCA-proficient cancers. Full Text Drug Discovery JOBS of the week Senior Research Fellow The University of Edinburgh Edinburgh, United Kingdom 1st Research Officer in Bioinformatics with focus on Metabolomics Umeå University, Computational Life Science Cluster (CLiC) Umeå, Sweden Director The Luc Hoffmann Institute Gland, Switzerland Postdoc Position in Quantitative Proteomics Children's Hospital Boston / Harvard Medical School Boston, MA, USA Professor of Medical Genetics University of Basel Basel, Switzerland More Science jobs from Drug Discovery EVENT Practical Aspects of Biopharmaceutical Drug Discovery 19.-24.09.11 Hinxton, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.